



MONTHLY DOSE
MARCH 2021

News for the Month

Company

- Lupin launches Penicillamine Tablets USP
- Cipla Gulf expands partnership with Alvotech for commercialization of biosimilars in Australia and New Zealand
- Shilpa Medicare enters women's intimate cleansing segment with SwatchShil
- Shilpa Medicare receives USFDA tentative approval for Apremilast Tablets, 10/20/30mg
- Cipla liquidates wholly-owned unit as part of internal reorganisation
- NATCO receives final approval for Everolimus tablets (generic for Afinitor) for the US market
- Lupin Pharma Canada announces partnership with Endoceutics for the commercialization of Intrarosa
- Sun Pharma subsidiary to acquire 12.5% stake in WRS Bioproducts
- Dr. Reddy's U.S. plant gets FDA observations
- AstraZeneca Pharma receives import and market permission from DGCI for Osimertinib tablets
- Bharat Biotech's Covaxin gets restricted emergency nod
- Sun Pharma, Dr. Reddy's, Aurobindo recall products in the US market
- Alkem launches Brivaracetam in India under the brand name Brivasure for treatment of epilepsy
- Strides receives USFDA approval for Potassium Chloride for Oral Solution
- Strides Pharma raises Rs1,415cr in Series B, C funding
- Strides' biopharma arm partners RDIF to supply Covid-19 vaccine
- Biocon incorporates wholly-owned subsidiary Biofusion Therapeutics
- Glenmark and Bausch Health join together to commercialize RYALTRIS nasal spray in Canada
- Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride ER Capsules
- Cipla partners with SIGA Technologies to address challenge of AMR
- Alkem partners with Tata Memorial Hospital to establish state of art cancer care facility at Muzaffarpur, Bihar
- Pfizer begins early-stage study of oral drug to combat coronavirus
- Zydus announces settlement of patent litigation for generic Revlimid in US
- Remdac (Remdesivir) from Zydus now more affordable at Rs899
- Sun Pharma, Lupin, Cadila and Torrent invest in ABCD Technologies LLP
- Zydus Cadila receives tentative nod from USFDA to market two HIV drugs
- Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil
- Dr. Reddy's expects Sputnik V vaccine to get approval from Indian regulator in next few weeks: Official
- Bharat Biotech, Biovet, Sapigen Biologix sign collaborative research agreement with CSIR-IICT

Industry

- Govt approves 33 API applications with over Rs5,000cr committed investment under PLI scheme
- India imposes anti-dumping duty on Chinese antibacterial drug Ciprofloxacin Hydrochloride
- Pharma Industry to spend USD4.5bn on digital transformation by 2030
- India on its way to become world's Pharma Hub
- NITI Aayog outlines a range of investment opportunities in healthcare sector

Global

- AstraZeneca's Covid-19 vaccine shows 79% efficacy in US trial
- Amgen to buy Five Prime Therapeutics in USD1.9mn deal

Source: Media Reports and Company Press Releases

Tentative ANDA Approvals:

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
Cadila	Emtricitabine and Tenofovir Disoproxil Fumarate Tablets	100/150mg, 133/200mg, 167/250mg	Helps to decrease the amount of HIV in the body so that the immune system can work better	Truvada (Gilead)	-
Shilpa Medicare	Apremilast Tablets	10/20/30mg	Used in the treatment of psoriatic arthritis	OTEZLA (Celgene)	USD2.4bn

Source: Media Reports and Company Press Releases

Final ANDA Approvals:

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
Natco	Everolimus Tablets	2.5/5/7.5mg	Indicated for the treatment of breast cancer	Afinitor (Novartis AG)	USD712mn (annual sales)
Alembic	Testosterone Gel	1.62% (20.25 mg/1.25gm actuation)	Indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone	AndroGel (AbbVie Inc.)	USD86mn
Glenmark	Diltiazem Hydrochloride ER Capsules	60/90/120mg	Indicated for the treatment of hypertension	Cardizem (Biovail Laboratories Inc.)	USD56.7mn
Strides	Potassium Chloride for Oral Solution	20 mEq	Indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis	Potassium Chloride (Pharma Research Software Solution, LLC.)	USD56mn
Glenmark	Chlorpromazine Hydrochloride Tablets	10/25/50/100/20 mg	Used to treat certain mental/mood disorders (such as schizophrenia, psychotic disorders)	Thorazine (GlaxoSmithKline)	USD108.6mn (annual sales)

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Aarti Drugs Ltd	695	10.0%	-9.9%	37.4%
Abbott India Ltd	14989	3.4%	-9.2%	-3.0%
Ajanta Pharma Ltd	1793	2.0%	11.2%	31.3%
Alembic Ltd	103	1.3%	-2.0%	188.1%
Alembic Pharmaceuticals Ltd	965	4.5%	3.0%	80.9%
Alkem Laboratories Ltd	2772	-1.6%	-0.2%	19.0%
Apollo Hospitals Enterprise Ltd	2903	-5.8%	35.1%	155.1%
AstraZeneca Pharma India	3010	-12.9%	-30.0%	25.9%
Aurobindo Pharma Ltd	882	1.0%	10.7%	113.4%
Biocon Ltd	409	3.4%	-8.7%	51.1%
Bliss GVS Pharma Ltd	99	-43.5%	-42.1%	-2.1%
Cadila Healthcare Ltd	441	1.3%	11.6%	65.1%
Caplin Point Laboratories Ltd	404	-13.5%	-27.0%	43.1%
Cipla Ltd	815	3.3%	5.2%	92.7%
Divi's Laboratories Ltd	3630	4.8%	19.1%	82.6%
Dr. Reddy's Laboratories Ltd	4516	1.4%	-12.9%	44.9%
Dr. Lal PathLabs Ltd	2707	16.0%	44.1%	93.2%
Eris Lifesciences Ltd	604	1.6%	12.3%	64.0%
FDC Ltd	286	2.4%	-19.8%	45.8%
Fortis Healthcare Ltd	199	16.6%	47.1%	57.9%
GSK Pharmaceuticals Ltd	1440	-1.0%	-8.5%	15.7%
Glenmark Pharmaceuticals Ltd	465	-0.7%	-3.7%	125.5%
Granules India Ltd	303	-11.2%	-21.0%	111.2%
Gufic Biosciences Ltd	114	-4.2%	26.9%	142.4%
HealthCare Global Enterprises Ltd	191	13.8%	58.4%	154.7%
Hester Biosciences Ltd	1917	10.6%	12.6%	107.2%
Hikal Ltd	144	-10.3%	-24.9%	105.0%
Indoco Remedies Ltd	289	-3.0%	12.7%	37.8%
Indraprastha Medical Corp. Ltd	54	0.6%	7.0%	58.3%
IOL Chemicals and Pharma Ltd	551	0.4%	-24.1%	212.6%
IPCA Laboratories Ltd	1903	0.0%	-12.2%	37.1%
J.B. Chemicals & Pharma Ltd	1254	9.3%	26.9%	146.6%
Jubilant Life Sciences Ltd	680	-12.8%	-6.7%	173.4%
Kopran Ltd	105	-11.1%	11.5%	314.0%


Source: BSE website;
All prices are as on 31st March 2021

BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Laurus Labs Ltd	362	-0.4%	26.1%	461.1%
Lincoln Pharmaceuticals Ltd	225	-4.3%	-13.7%	67.9%
Lupin Ltd	1021	-0.2%	1.4%	73.1%
Mangalam Drugs and Organics Ltd	99	-15.5%	-24.4%	227.5%
Marksans Pharma Ltd	50	-11.0%	-0.7%	259.4%
Medicamen Biotech Ltd	534	-15.9%	32.4%	195.5%
Merck Ltd	6193	-6.2%	23.8%	69.9%
Morepen Laboratories Ltd	32	10.5%	31.0%	237.0%
Narayana Hrudayalaya Ltd	406	-6.6%	13.4%	64.1%
Natco Pharma Ltd	825	0.7%	-13.2%	63.0%
Nectar Lifesciences Ltd	19	-8.6%	-17.9%	88.1%
Neuland Laboratories Ltd	2088	1.7%	81.9%	636.6%
Novartis India Ltd	552	-10.2%	-11.0%	9.9%
Opto Circuits India Ltd	3	-33.9%	-44.0%	71.0%
Panacea Biotec Ltd	177	-9.3%	-3.8%	62.0%
Pfizer Ltd (India)	4521	-2.4%	-7.7%	12.3%
Piramal Enterprises Ltd	1752	-6.8%	39.9%	86.6%
Poly Medicure Ltd	818	13.2%	78.8%	247.0%
RPG Life Sciences Ltd	387	-7.1%	-2.9%	127.1%
Sanofi India Ltd	7877	-4.7%	-8.8%	26.2%
Shalby Ltd	101	-5.3%	14.3%	117.8%
Shilpa Medicare Ltd	334	-9.1%	-40.4%	36.5%
SMS Pharmaceuticals Ltd	124	-7.9%	40.5%	366.8%
Strides Shasun Ltd	845	1.1%	17.3%	161.8%
SPARC Ltd	142	-14.6%	-18.4%	46.8%
Sun Pharmaceutical Industries Ltd	598	-1.1%	19.4%	69.7%
Suven Life Sciences Ltd	70	-16.9%	39.5%	229.0%
Syngene International Ltd	543	-2.6%	-1.8%	124.9%
Thyrocare Technologies Ltd	903	-1.9%	19.1%	82.2%
Torrent Pharmaceuticals Ltd	2541	4.2%	-9.2%	28.9%
Unichem Laboratories Ltd	309	-4.0%	26.4%	104.4%
Vimta Labs Ltd	161	-2.5%	36.0%	171.6%
Vivimed Labs Ltd	16	-4.8%	-18.3%	118.3%
Wockhardt Ltd	414	-17.1%	40.7%	139.9%

Source: BSE website;
All prices are as on 31st March 2021

NIFTY PHARMA COMPANIES					
Company	Price (Rs)	Mcap (Rsmn)	Change		
			1 M	6 M	12 M
Aurobindo Pharma Ltd.	882	516534	0.96%	10.7%	113.4%
Biocon Ltd.	409	490560	3.4%	-8.7%	51.1%
Cadila Healthcare Ltd.	441	451317	1.3%	11.6%	65.1%
Cipla Ltd.	815	657367	3.3%	5.2%	92.7%
Divi's Laboratories Ltd.	3630	963664	4.8%	19.1%	82.6%
Dr. Reddy's Laboratories Ltd.	4516	750808	1.4%	-12.9%	44.9%
Glenmark Pharmaceuticals Ltd.	465	131081	-0.7%	-3.7%	125.5%
Lupin Ltd.	1021	462736	-0.2%	1.38%	73.1%
Piramal Enterprises Ltd.	1752	395143	-6.8%	39.9%	86.6%
Sun Pharmaceutical Industries Ltd.	598	1433843	-1.1%	19.4%	69.7%

Source: NSE website, Company Research; All prices are as on 31st March 2021



Source: NSE website



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products. PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research Analyst has served as officer, director or employee of the subject company: NO

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:
Progressive Share Brokers Pvt. Ltd.
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai-400053;
www.progressiveshares.com
Contact No.:022-4077500.

Compliance Officer:
Mr. Shyam Agrawal,
Email Id: compliance@progressiveshares.com,
Contact No.:022-4077500.